Hematologic Malignancies – XPOVIO (selinexor)

Solid Tumor Malignancies – Selinexor

Additional Oncology Programs – Eltanexor

Area of TherapyPhase IPhase IIPhase III
Myelodysplastic syndromes (alone or in combo with hypomethylating agents) | KCP-8602-801
Phase I
Phase II
Phase III

Coming soon



Antegene licensed rights to selinexor, eltanexor, verdinexor, and KPT-9274 in China, South Korea, Australia and additional Asia Pacific markets, excluding Japan.

Anivive holds exclusive worldwide rights to research, develop, and commercialize verdinexor only for the treatment of cancer in companion animals